Podcasts about immune

Lyme Disease is becoming more common and many people don't even know they have it, which means it often goes untreated. And while you're waiting for your doctor to diagnose you, they'll often shrug off your other symptoms and say thing like "it's all in your head"....   TOPICS DISCUSSED IN THIS EPISODE: Why mental illness is more biological than psychological The brain scan that shows inflammation MRIs, your doctor and blood work miss Why some people get infected and never recover - and why some people do Childhood infections like Strep can cause full blown psychiatric changes that are often called ADHD or anxiety PANS, PANDAS, Lyme, Mold and more Autoimmunity and Lyme Disease How these disease can hijack your DNA   More from Dr. Eboni Cornish + the Amen Clinics: Clinic Website: www.amenclinics.com Instagram: @dr.ebonicornish Email (Assistant): drcornishassist@amenclinics.com Phone (Virginia Clinic): 703-880-4000     Leave us a Review: https://www.reversablepod.com/review   Need help with your gut? Visit my website gutsolution.ca to join a program: Get help now   Contact us: reversablepod.com/tips    FIND ME ON SOCIAL MEDIA: Instagram  Facebook  YouTube         

On this episode of Vitality Radio, Jared shares three powerhouse supplements that may not be “new,” but are being used in some of the most impactful ways yet. First up is a clinically studied lutein and zeaxanthin complex that supports eye health, blue light protection, and even cognitive performance—delivered in a delicious gummy called Screen Eyes. Next, Jared breaks down monolaurin, a coconut-derived compound that supports immune resilience by targeting lipid-coated viruses like herpes, Epstein-Barr, and influenza—especially when paired with L-lysine and vitamin C. And finally, he explores two innovative magnesium-based powders from Kal - Clean Out Magnesium and Gut Magnesium, each designed to promote healthy regularity and support cleansing protocols. If you've struggled with constipation or want to fine-tune your immune and visual wellness, this is an episode you don't want to miss.Products:Zhou Screen Eyes Blue Light FormulaMonolaurin & LysineVital-C ImmunityNano-SilverKAL Clean Out Magnesium PowderKAL Gut Magnesium PowderVital 5 Magnesium BisglycinateAdditional Information:#209 VR Short: Centrum SucksVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

YouTube link: https://youtube.com/live/N4rkX1nsfpcSupport the show

ReferencesFront. Immunol., 22 February 2024Sec.Multiple Sclerosis and Neuroimmunology Volume 15 Arthritis Care Res (Hoboken). 2024 Aug 7;76(11):1451–1460Nat Immunol. 2024 Apr 8;25(5):778–789Lake, G 1972 "From the Beginning" ELP Trilogy lp.https://music.youtube.com/watch?v=hsJ9YXHqnr8&si=NoG1BHKOtrFNYItmJoel, B. 1972. "Scenes from An Italian Restaurant. Yhe Stranger lphttps://music.youtube.com/watch?v=rdAvFvDVXSk&si=_BhtdE6WKN2J80FV

From the 2024 Society for Leukocyte Biology meeting, Cindy and Brianne talk with Darren Lee to discuss his career, how he got interested in immunology of the eye, and how his team visualizes immune responses of the eye in real time with the hope of better understanding autoimmune uveitis. Hosts: Cindy Leifer and Brianne Barker Guest: Darren Lee Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server The eye is an immunosuppressive environment (Adv Drug Delivery Rev 2023) Tregs control autoimmune uveitis (Sci Rep 2025) TIGIT, Tregs, and autoimmune uveitis (J Leuk Biol 2024) Society for Leukocyte Biology Time stamps by Jolene Ramsey. Thanks! Music by Tatami. Logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv Information on this podcast should not be construed as medical advice.

This episode was recorded at the 2025 Florida Ruminant Nutrition Symposium.  Dr. Baumgard begins with an overview of his presentation, “Importance of gut health to drive animal performance and health.” He notes the metabolic and inflammatory fingerprint of all stressors is essentially the same, indicating they likely all emanate from the gut. Overall, we're gaining a better understanding of how typical on-farm stressors negatively influence gut barrier function. He thinks the most likely mechanism of leaky gut is the immune cell known as a mast cell. When an animal or human is stressed, the enteric nervous system releases corticotropin-releasing factor, which binds to the mast cell, the mast cell degranulates, and the former contents of the mast cell (TNF-alpha, proteases, histamine, etc.) causes the gut to become leaky. (4:20)Once the GI tract barrier becomes compromised, antigens like lipopolysaccharide (LPS) can infiltrate, stimulating the immune system. Immune activation causes loss of appetite much like any other infection. The gut heals fairly quickly upon removal of the stressor(s), and the gut can also acclimate to stress such that the early stages of a stress event are more severe than later stages. Strategies to combat leaky gut remain scarce, and there is no silver bullet. There are a variety of dietary strategies to target the gut permeability issue itself. Another approach would be to bind pathogens or curb their proliferation at the membrane of the small intestine. (7:06)Dr. Neiehues asks if an antihistamine would work on gut mast cells the way it does in other body systems. Dr. Baumgard isn't sure that's ever been looked at, although there have been some studies in pigs using a product targeted to prevent mast cell degranulation. Dr. Nelson wonders if we should interfere in some of these processes because they're obviously there for a reason. Panelists discuss stress events related to parturition and transition, particularly for first-calf heifers. Dr. Baumgard notes that stacking stressors on top of one another compromises an animal's ability to tolerate stress. (9:28)We know stress can cause ulcers in humans and horses - what about ruminants? Dr. Baumgard thinks it is likely that it's happening, but we aren't looking for it. Few animals who die on-farm do receive a thorough postmortem exam. It could also be that these types of insults to the gut are not visible to the naked eye. (19:11)Dr. Nelson asks what makes some cows, despite all the challenges, able to be up and milking 150 pounds a day in no time after calving. What makes them unique? Dr. Baumgard lists some possibilities, including lower pathogenic inflammation than other cows, less tissue trauma damage to the uterus during calving, and lower sensitivity to immune activation. The panel disagrees with the notion that high-producing cows are stressed. (23:16)Dr. Niehues and Dr. Baumgard trade stories of experiments where cows maintained production even with high stress and inflammatory markers. The panel goes on to discuss subclinical infections and their impact on transition cows. Dr. Nelson notes there are retrospective datasets where cows who had metritis showed decreased feed intake even before calving. Dr. Baumgard feels that the decrease in intake has been incorrectly assumed to be the cause of the metritis. He says the decrease in intake is often around two weeks before calving and he doesn't think it's a coincidence that at the same time, the mammary gland is initiating lactogenesis. He hypothesizes the mammary gland is causing an immune response, resulting in a decrease in intake. Dr. Nelson wonders if measuring somatic cell counts of colostrum would show any differences in mammary gland inflammation during this prepartum period. (29:18)Panelists share their take-home thoughts. (42:02)Please subscribe and share with your industry friends to invite more people to join us at the Real Science Exchange virtual pub table.  If you want one of our Real Science Exchange t-shirts, screenshot your rating, review, or subscription, and email a picture to anh.marketing@balchem.com. Include your size and mailing address, and we'll mail you a shirt. 

ReferencesFront. Immunol., 22 February 2024. Sec. Multiple Sclerosis and Neuroimmunology Volume 15 Nat Cell Biol. 2019 Mar; 21(3): 397–407.CELL 2006. Volume 126, Issue 3, 11 August Pages 503-514Valenti, D. 1971. "Dont Cry My Lady Love"https://music.youtube.com/watch?v=Aqt0yhGfC1s&si=fXpd1HifSgtEHtpbLennon/McCartney. 1966. "For No One"Revolver. lp.https://music.youtube.com/watch?v=ELlLIwhvknk&si=ZgDZXKn_UPC3RHBmMozart, WA. 1773. Symphony 25 in G Minorhttps://music.youtube.com/watch?v=707oHEGF6l8&si=rwJRSJ2CeYfYVIas

In this episode, host Alyssa Watson, DVM, is joined by John M. Thomason, DVM, MS, DACVIM (SAIM), to talk about his recent Clinician's Brief article, “Top 4 Primary Immune-Mediated Disorders in Dogs.” In part 1 of this 2-part conversation, Dr. Thomason focuses on the diagnosis and management of IMHA and IMTP. You'll hear vital details for both conditions including the right way to handle blood smears and slide agglutination, which IMHA cases are hypercoagulable (spoiler: all of them), and if vincristine actually helps in IMTP (spoiler again: it does).Resources:https://www.cliniciansbrief.com/article/anemia-thrombocytopenia-immune-disorder-dogshttps://www.zoetisus.com/products/dogs/librelaContact:podcast@instinct.vetWhere To Find Us:Website: CliniciansBrief.com/PodcastsYouTube: Youtube.com/@clinicians_briefFacebook: Facebook.com/CliniciansBriefLinkedIn: LinkedIn.com/showcase/CliniciansBrief/Instagram: @Clinicians.BriefX: @CliniciansBriefThe Team:Alyssa Watson, DVM - HostAlexis Ussery - Producer & Multimedia Specialist

ReferencesGuerra. DJ. 2025. Unpublished LecturesFront. Immunol.,2024. 22 February Sec. Multiple Sclerosis and Neuroimmunology Volume 15 .Annals of Clinical & Laboratory Science.2022.vol. 52, no. 5 pp763-771.Mol Biosyst. 2014 Oct;10(10):2505-8. Frey/Henley. 1973. "Desperado" The Eagleshttps://music.youtube.com/playlist?list=OLAK5uy_k3UBMdBe0k-PWX6y1VCLJZVJogoUaKEco&si=9kkmSQG5xcdpbINRWelch, B 1973. "Emerald Eyes" Fleetwood Mac.Mystery to Me lp.https://music.youtube.com/watch?v=DnQM535xV-U&si=sRsNuXaEJ1A4VWPJ

ReferencesRespirology. 2017 Feb;22(2):315-321Advances in Biological Regulation Volume94, December 2024, 101058Leach, Donavan.1967. "Mountain Jam" Allman Brothers. Eat a Peach lphttps://music.youtube.com/watch?v=5-3L1MFBKZY&si=tO7pVzAAw9jHsw9ILamm. R 1972 "Saturday in the Park" on Chicago V lp.https://music.youtube.com/watch?v=HjylD7esXDo&si=Bu53QElJo8RDAwgN

Hormonal shifts in perimenopause and menopause can do more than throw off your cycle—they can actually stir up inflammation, spark strange symptoms, and even trigger immune responses that leave you wondering, what is going on with my body? If you've ever felt like your symptoms don't quite “fit in a box,” this conversation is for you. I sit down with Dr. Tania Dempsey—a brilliant MD and expert in complex, multi-system diseases—to talk about Mast Cell Activation Syndrome (MCAS), why it's often missed in women, and how hormones can play a huge role in triggering it. This episode connects the dots between your immune system, your hormones, and all those mystery symptoms no one's been able to explain. Dr. Tania breaks it down—how mast cells work, what happens when they go rogue, and why midlife women are seeing a rise in things like histamine intolerance, inflammation, and post-viral flare-ups (yes, COVID included). She shares what to look out for, what testing often misses, and how therapies like low-dose naltrexone and even ozone can make a difference. You'll also love hearing Dr. Tania's heart for educating both patients and physicians so women can finally get the answers they deserve. And speaking of support, I've been sipping on my new Mighty Maca Mango lately, and it's a summer fave. Light, zesty, and still packed with all the hormone-balancing goodness of the original, it's perfect over ice or made into popsicles. Check it out at dranna.com—you'll be hooked.   Key Timestamps: [00:00:00] Introduction. [00:01:28] Mast cell activation syndrome. [00:06:51] Mast cell activation syndrome prevalence. [00:08:12] Immune system and estrogen dominance. [00:09:44] Symptoms of MCAS [00:12:08] Hormonal impacts on mast cells. [00:15:42] Long COVID and mast cell activation. [00:20:51] Perfect storm of infections. [00:23:41] Plasmapheresis for mast cell activation. [00:29:04] EMF sensitivity and health effects. [00:30:11] EMF shielding devices and methods. [00:34:44] Fatigue in mast cell activation.   Memorable Quotes: "My mission is really to figure out how can we get it to the point where this could be potentially, quote-unquote, cured. " [00:25:16] – Dr. Tania Dempsey "I'm going to help the world, one patient at a time, by giving them this information so they can help themselves." [00:37:11] – Dr. Tania Dempsey   Links Mentioned: Mighty Maca Mango: https://drannacabeca.com/products/mighty-maca   Connect with Dr. Tania Dempsey: Mast Cell Matters Podcast: https://drtaniadempsey.com/podcast/ Website: https://drtaniadempsey.com/ Instagram: https://www.instagram.com/drtaniadempseymd/ Facebook: https://www.facebook.com/taniadempseymd/ LinkedIn: https://www.linkedin.com/in/taniadempsey/ YouTube: https://www.youtube.com/@DrTaniaDempsey   Connect with Dr. Anna Cabeca: Website: https://drannacabeca.com/pages/show Instagram: https://www.instagram.com/thegirlfrienddoctor/ YouTube: https://www.youtube.com/@thegirlfrienddoctor TikTok: https://www.tiktok.com/@drannacabeca   Produced by Evolved Podcasting: www.evolvedpodcasting.com

ReferencesGuerra, DJ. 2022. Journal of Disease and Global Health.15(3): 22-47, 2022 ISSN: 2454-1842, NLM ID: 101664146Acta Pharm Sin B. 2018 Oct; 8(6):862–880. Anal Cell Pathol (Amst). 2018; 2018: 787.1814. Exp Cell Res . 2015 Nov 15;339(1):20-34Barry, C. 1959 "Back in the USA"https://music.youtube.com/watch?v=XVukAcLqHFI&si=XOg6AR5y8Io6LaAtDickinson, J.1768 'The Liberty Song"https://youtu.be/OvLdawL3wHM?si=Jqmr27BYda3IyyQD Key. FS. 1814. "The National Anthem" (Star Spangled Banner" https://music.youtube.com/watch?v=wo_VTU4pxrU&si=-wLpOEQYV9QdTFVy

Today's Case A 26-year-old female with no significant medical history presents with hepatitis B diagnosed 6 months ago from routine laboratory testing. She is asymptomatic. Today's Reader Jared Fehlman is an Internal Medicine Resident at Huntington Health Hospital in Pasadena, California. About Dr. Raj Dr Raj is a quadruple board certified physician and associate professor at the University of Southern California. He was a co-host on the TNT series Chasing the Cure with Ann Curry, a regular on the TV Show The Doctors for the past 7 seasons and has a weekly medical segment on ABC news Los Angeles. More from Dr. Raj ⁠The Dr. Raj Podcast⁠ ⁠Dr. Raj on Twitter⁠ ⁠Dr. Raj on Instagram⁠ Want more board review content? ⁠USMLE Step 1 Ad-Free Bundle⁠ ⁠Crush Step 1⁠ ⁠Step 2 Secrets⁠ ⁠Beyond the Pearls⁠ ⁠The Dr. Raj Podcast⁠ ⁠Beyond the Pearls Premium⁠ ⁠USMLE Step 3 Review⁠ ⁠MedPrepTGo Step 1 Questions⁠ ⁠MedPrepTGo Step 2 Questions⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

 Parshat Shelakh 

This episode originally aired as #395 on 1/13/24. It's an oldie but goodie so we are sharing it again! What is Aged Garlic Extract (A.G.E.) and how is it different from the garlic we eat? Can this one thing actually lower cholesterol, improve insulin resistance, keep bones strong, boost immunity and detoxification, and prevent dementia? We tend to compartmentalize our bodily systems, but they are all connected and the cardiovascular system is at the head of them all. Learn the science behind how A.G.E. can impact all of our systems, how to take it, how much to take, and what the research actually shows, on this episode of Vitality Radio, where Jared interviews Jim LaValle all about Kyolic Aged Garlic Extract. You'll learn its many benefits and how to use it to improve your overall health. Products:Kyolic Aged Garlic ProductsAdditional Information:#278: The Incredible Benefits of Aged Garlic ExtractLipid tests discussed: NMR LipoProfile® TestCardio IQ®Visit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

In this insightful episode, Dr. Jill Carnahan sits down with Dr. Amy Proal as they delve into the emerging connections between Bartonella infections and Long Covid, revealing new research that may reshape our understanding of chronic illness. Discover how the MTOR pathway plays a pivotal role in pathogen survival and mitochondrial health, and how drugs like rapamycin could be game-changers in managing these infections. We also explore Mast Cell Activation Syndrome (MCAS) and its links to unresolved infections, offering hope for treatment beyond medication. Key Discussions ①  Bartonella and Long Covid:

SUMMER SALE: THRU- JULY 10 -->15% OFF SUPPLEMENTS with SUMMER15 -->DianeKazer.com/SHOP -->FULLMOONPARASITECLEANSE.COM (with new Peptide Module inside the course!) -->DianeKazer.com/SHOP -->DianeKazer.com/VIP -->DianeKazer.com/PATIENT -->DianeKazer.com/PURCHASEPEPTIDES -->DianeKazer.com/PURCHASEPEPTIDESVIP -->DianeKazer.com/FMCFREEMODULE We're living in a parasite paradise — and most people have NO idea what's fueling it. Which is exactly why today on our CHI Podcast: DOC TALK, I'm talking about why I am seriously leveling up our next Full Moon Parasite Cleanse Challenge…with my new Peptide module! And how you can get access to my all-new Peptide Module for the next July 10 Full Moon! Inside the PARASITE PEPTIDE module, you'll learn:

Liver cancer, especially hepatocellular carcinoma (HCC), remains a major health concern worldwide. In Latin America, the situation becomes more difficult due to limited access to advanced treatments and the high prevalence of underlying liver diseases. A recent research paper, published in Volume 16 of Oncotarget by researchers from Argentina, Brazil, Chile, and Colombia, offers valuable insights into how patients in the region respond to a widely used immunotherapy regimen. This real-world study explores both the effectiveness of treatment and the risks of immune-related side effects. Understanding Hepatocellular Carcinoma: Why It is So Difficult to Treat Hepatocellular carcinoma is often diagnosed at an advanced stage and frequently occurs in people with pre-existing liver conditions such as cirrhosis. Standard treatments like surgery or local therapies are not always possible in these cases. In recent years, the combination of two drugs—atezolizumab and bevacizumab—has shown promise in extending survival. However, most of the evidence comes from controlled clinical trials that may not represent the realities faced by healthcare providers and patients in Latin America. The Study: Immunotherapy for Hepatocellular Carcinoma in Latin America In a multicenter study titled “Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma,” led by Leonardo Gomes da Fonseca from Hospital das Clínicas, Universidade de São Paulo, Brazil, and Federico Piñero from Hospital Universitario Austral, Argentina, researchers aimed to fill that gap. The study included 99 patients with advanced HCC from Argentina, Brazil, Chile, and Colombia. All patients received the combination of atezolizumab and bevacizumab. The main objectives were to assess how frequently immune-related side effects, known as immune-related adverse events (irAEs), occurred and whether these events affected overall survival. Full blog - https://www.oncotarget.org/2025/07/02/immunotherapy-safety-for-hepatocellular-carcinoma-in-latin-america-insights-from-a-real-world-study/ Paper DOI - https://doi.org/10.18632/oncotarget.28721 Correspondence to - Federico Piñero - fpinerof@cas.austral.edu.ar Video short - https://www.youtube.com/watch?v=gk3oQwzIC-E Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28721 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, liver cancer, immunotherapy, adverse events, immunology, real-world To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

In this episode of The Poultry Nutrition Blackbelt Podcast, Dr. Elijah Kiarie from the University of Guelph discusses the nutritional challenges of β-mannans in soybean meal and the value of β-mannanase supplementation in poultry diets. He breaks down the metabolic, immune, and microbiome effects of fiber and how enzyme technologies are advancing feed efficiency. Listen now on all major platforms!"β-mannanase supplementation helps neutralize β-mannans, improving nutrient absorption and reducing immune activation."Meet the guest: Dr. Elijah Kiarie received his Ph.D. and postdoctoral training in monogastric nutrition from the University of Manitoba. He is a Professor at the University of Guelph and holds The McIntosh Family Professorship in Poultry Nutrition. His research bridges fundamental and applied science to advance poultry productivity through innovations in early-life nutrition, enzyme technologies, and sustainable feed strategies.Liked this one? Don't stop now — Here's what we think you'll love!What you'll learn:(00:00) Highlight(01:24) Introduction(03:51) Role of β-mannans(05:49) Immune system activation(07:25) β-mannanase supplementation(08:27) Enzyme technology role(09:20) Microbiota and fermentation(12:25) Closing thoughtsThe Poultry Nutrition Blackbelt Podcast is trusted and supported by innovative companies like: BASF* Kerry* Kemin- Poultry Science Association- Anitox

Want better digestion, stronger immunity, and even improved mental clarity?

It's now well established that chronic stress leads to an out-pouring of cortisol and with that, a gradual depletion of DHEA. DHEA is a prohormone – a natural building block for hormones our bodies make.Over time, this hormonal imbalance can lead to brain fog, thinning bones, weight gain, low sex drive and poor Immune function.Maintaining proper DHEA levels in the body is important to your overall health and may lead to Increased energy, enhanced mood and focus, sound sleep, and better looking skin.Guest: Joining us today is Hugh Woodward, He is the President of Health2Go, Inc the makers of Twist 25 DHEA cream. Hugh is a subject matter expert on DHEA dedicating nearly 2 decades of his life studying the medical research about it, and starting a company to research, develop the safest most effective DHEA supplement that can be made and distributing it.In 2007 Mr. Woodward started Health2Go, Inc. to research and develop leading edge anti-aging and wellness products and bring them to people conveniently and cost effectively.Quality matters when supplementing with DHEA. Twist 25 DHEA Cream puts exactly what the body makes naturally – bioidentical DHEA -in the skin, where the body processes DHEA.  As a base building block for hormones, DHEA gives the body a key foundation it uses to make hormones, (especially the androgens our feel-good hormones.)Visit Twist25.com to learn more and order online. Or call 888-489-4782 that's888-489-4782. Look your best, feel your best with Twist 25 DHEA cream.Listeners can save 15% OFF using the code: forever at checkout.

Struggling with a bloated stomach after eating or chronic abdominal distension? In this episode, I'll explain why dysfunction in three major systems causes bloating and reveal 5 evidence-based microbiome fixes that can help reduce stomach bloating while healing your gut naturally.   Start healing with us! Learn more about our virtual clinic:  https://drruscio.com/virtual-clinic/   Free downloadable Low FODMAP Diet guide: https://drruscio.com/guides/get-low-fodmap-diet-guide/   Featured products: Elemental Diet: https://store.drruscio.com/products/elemental-heal Triple Therapy Probiotics: https://store.drruscio.com/products/triple-therapy-probiotic Biota Clear Series: https://store.drruscio.com/search?q=biota+clear Biota Dissolve: https://store.drruscio.com/products/biota-dissolve VaguStim: https://vagustim.io/  

In this episode, we dive into a two-part story of intrigue starting from a paradigm shift in understanding of T cell biology because of a mouse model of post-measles encephalopathy, to the eventual recognition of the IL-23/17 immune axis. •    Intro 0:01 •    In this episode 0:12  •    Interleukin-17 (IL-17) is a relatively recent discovery 1:34 •    The beginning of TH-17 2:20 •    Looking at autoimmune encephalopathy: A story of measles 03:30 •    1790's woman with post measles inflammatory process in the brain 10:26 •    What is causing post-infection encephalitis? 12:00 •    Acute disseminated encephalomyelitis 12:30 •    How did we find out the immune system was behind this - The rabies vaccine 13:09 •    Similarity between the rabies vaccine and infections like measles 16:04 •    T-cell lymphocytes 17:12 •    The forgotten thymus 18:00 •    What's the function of T-cells? 19:35 •    How do you tell T-cells apart? 21:14 •    The Human Leukocyte Differentiation Antigens Party 24:05 •    The godfather of T-cells 24:45 •    The TH-1 and TH-2 axis 27:30 •    Experimental Autoimmune Encephalomyelitis model screwed everything up 29:16 •    Interferon gamma 32:32 •    What's missing? IL-23 surprise 33:40 •    IL-17 in the 1990's 36:44 •    The world is introduced to TH-17 39:12 •    Let's recap what we learned 40:30 •    That is the end! 42:30 •    Thanks for listening 42:39 We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum. References: Bashyam H. J Exp Med. 2007;doi:10.1084/jem.2042fta Bennetto L, et al. J Neurol Neurosurg Psychiatry. 2004;doi:10.1136/jnnp.2003.034256 Berche P. Presse Med. 2022;doi:10.1016/j.lpm.2022.104149 El-behi M, et al. J Neuroimmune Pharmacol. 2010;doi:10.1007/s11481-009-9188-9 Gooderham MJ, et al. J Eur Acad Dermatol Venereol. 2018;doi:10.1111/jdv.14868 Hawkes JE, et al. J Immunol. 2018;doi:10.4049/jimmunol.1800013 Rogozynski N, et al. Immunol Lett. 2024;doi:10.1016/j.imlet.2024.106870 Sospedra M, et al. Annu Rev Immunol. 2005;doi:10.1146/annurev.immunol.23.021704.115707 Steinman L. Nat Med. 2007;doi:10.1038/nm1551 Disclosures: Brown reports no relevant financial disclosures.

Microplastics In this series, the host Catherine Glass welcomes Stacy Loeb, a renowned urologist and lifestyle medicine advocate, to explore the growing impact of environmental factors on men's health. From the risks of microplastics and the benefits of plant-based diets to the carbon cost of prostate procedures, these conversations challenge conventional clinical perspectives and offer practical, planet-conscious solutions for modern urology. Timestamps:   1:01 – Getting into urology 1:52 – Pioneering environmental health in urology 2:28 – Patient perspectives on plastic exposure 4:25 – Microplastics in testicular tissue 7:06 – Plastics are everywhere 9:30 – Immune response to microplastics 10:20 – Microplastics in female genitalia and sanitary product  

Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency.  So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated.  Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations.  And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:    Dr. Diwakar Davar    @diwakardavar    Dr. Jason Luke @jasonlukemd Follow ASCO on social media:     @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn   Disclosures:     Dr. Diwakar Davar:      Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences     Consulting or Advisory Role: Instil Bio, Vedanta Biosciences     Consulting or Advisory Role (Immediate family member): Shionogi     Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences     Research Funding (Inst.): Zucero Therapeutics     Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy     Dr. Jason Luke:     Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX     Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine     Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure     Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)     Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

You reckon you're immune to propaganda and disinformation, right? A critical thinker who sees through the rubbish.I thought the same - until I realised I'm way more likely to believe something if it backs up what I already think.That's not a personal flaw. It's how we're all wired. But we need to get better at spotting it, because it's fuelling polarisation and making it harder to have real conversations with people we disagree with.And with AI making it even harder to tell what's real, it's only going to get trickier.If we want to tackle big issues together, we've got to become more sceptical, more media literate, and better at asking:Where's the evidence? What's the source? Is there consensus?This episode is designed to help you do exactly that - understand and analyse the information out there.In this episode I talk about:What confirmation bias actually isA proper breakdown of propaganda, misinformation, and disinformationHow extremist disinformation groups take holdReal examples of how disinformation can (and does) cost livesHow it delays action on the things that matter mostWhat to look for when spotting disinformationThe six main tactics companies and governments use to spread itAnd how we can start pushing backGiveaway! This week, we're giving away copies of Six Conversations We're Scared to Have by Deborah Francis White - a practical guide to having honest and respectful discussions on tough topics like politics, climate, and social issues. Join me over on Instagram to enter. Find our full podcast via the website here: https://www.nowthatswhaticall.com/Instagram: https://www.instagram.com/nowthatswhaticallgreen/You can follow me on socials on the below accounts.Instagram: https://www.instagram.com/briannemwest/TikTok: https://www.tiktok.com/@briannemwestLinkedIn: https://www.linkedin.com/in/briannemwest/For our latest big project, find out more about Incrediballs here: https://incrediballs.com/

Vi kender alle billederne af børshandlere, der råber og skriger på handelsgulvet på børsen på Wall Street, mens de desperat prøver at købe eller sælge. Men de seneste måneder har investorerne og børsmæglerne opført sig bemærkelsesværdigt roligt - til trods for krig i Mellemøsten, Donald Trumps fortsatte toldtrusler og generel ustabilitet i verden. Hør Finans Global og bliv klogere på, om investorerne er blevet mere immune over for toldtrusler og ufred, og hvad det i så fald betyder for virksomheder og verdensøkonomien. Gæst: Thomas Høy, global korrespondent, Finans. Vært: Mads Ring. Producer: Mads Ring. Foto: Richard Drew/AP.See omnystudio.com/listener for privacy information.

Text Dr. Lenz any feedback or questions This detailed podcast episode delves into the findings of a study on Chronic Fatigue Syndrome (CFS) using functional MRI and immune system analysis. The speaker explains the technology behind functional MRI and what it revealed about brain activity, specifically in the parietal temporal junction, which showed hypoactivity in CFS patients. The discussion extends to immune abnormalities, highlighting immune cell exhaustion, and hypothesizing links to persistent infections. The episode emphasizes the need for interdisciplinary, evidence-based approaches to treating these 'invisible' illnesses and calls for more integrated, patient-centric research. Other discussed topics include the limitations of current medical specialization and the need for generalist knowledge, the role of gut microbiome, and potential lessons from oncology on immune checkpoints.00:00 Introduction to Functional MRI01:48 Understanding Functional MRI Findings04:08 Immune System Insights04:54 Cancer Research and Immune Exhaustion09:01 Genetic Susceptibility and Long COVID10:33 Holistic Approach to Medicine13:34 Challenges in Treating CFS and Fibromyalgia15:38 Future Directions in Research22:40 Gut Microbiome and Immune Response25:41 Neurodivergence and Immune System29:25 Conclusion and Final Thoughts International Conference on ADHD in November 2025 where Dr. Lenz will be one of the speakers. Support the showWhen I started this podcast—and the book that came before it—I had my patients in mind. Office visits are short, but understanding complex, often misunderstood conditions like fibromyalgia takes time. That's why I created this space: to offer education, validation, and hope. If you've been told fibromyalgia “isn't real” or that it's “all in your head,” know this—I see you. I believe you. You're not alone. This podcast aims to affirm your experience and explain the science behind it. Whether you live with fibromyalgia, care for someone who does, or are a healthcare professional looking to better support patients, you'll find trusted, evidence-based insights here, drawn from my 28+ years as an MD. Please remember to talk with your doctor about your symptoms and care. This content doesn't replace personal medical advice.* ...

While tuberculosis is not a major health issue in New Zealand, worldwide it remains the leading infectious disease killer.   The vaccine against tuberculosis, called BCG, was first developed in France more than 100 years ago using a strain of bacteria that lost its disease-causing ability. Scientists refer to this as a live attenuated vaccine.   On Our Changing World, the Malaghan Institute's Dr Kerry Hilligan explains to Claire Concannon how this old vaccine is teaching researchers new tricks.

Vincent and Cindy discuss differences between MPox-specific T cell responses following infection and vaccination, and lymph node macrophage control of memory B cell localization and trafficking that might be important for choosing which arm to get a vaccine. Hosts: Vincent Racaniello and Cindy Leifer Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server Different T memory response to MPox infection or vaccination (Nat Comm 2025) Macrophages direct B cell recall responses after vaccination (Cell 2025) Time stamps by Jolene Ramsey. Thanks! Music by Tatami. Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv Information on this podcast should not be construed as medical advice.

Immune-related adverse events (AEs) are becoming more frequent in oncology patients receiving immunotherapy. To better understand emerging trends and education needs, the Association of Cancer Care Centers (ACCC) developed the Immuno-Oncology Census as part of its ongoing commitment to sharing up-to-date strategies for managing adverse events. In this episode, CANCER BUZZ speaks with Bat-ami Gordon, clinical research PhD candidate at the Icahn School of Medicine at Mount Sinai, who discusses best practices for cancer care providers to identify immune-related AEs caused by immunotherapy.   “Understanding the best practices for identification is going to be the best way we can start to implement better treatments for these immune-related adverse events.” – Bat-ami Gordon   Bat-ami Gordon Clinical Research PhD Candidate  Icahn School of Medicine Mount Sinai New York, NY      Additional Reading/Sources   Icahn School of Medicine at Mount Sinai ACCC Immune-Related Adverse Events Resources Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors ACCC Immuno-Oncology Census

This week brought another significant tornado outbreak to parts of Minnesota. Downtowns for the Twin Cities, Rochester and Duluth were spared from any storm damage, but are cities safer from tornadoes than rural parts of Minnesota? Does the urban heat island effect spare urban residents from a tornado tearing through their cities? “The urban heat island probably would not save you if the storm were in a position to enter that urban area,” said climatologist Kenneth Blumenfeld. “We should definitely disabuse ourselves of this myth.”Blumenfeld, who has researched urban tornados, said the probability of tornadoes striking skyscraper-filled cities like the Twin Cities, or smaller downtowns, are just as high as elsewhere. “All the big cities, [in] tornado prone regions like the Midwest, the South and the Great Plains, have relatively high amounts of tornado activity — it's a lesson for all of us that tornadoes can and do hit cities.”To hear the full conversation, click play on the audio player above or subscribe to the Climate Cast podcast.

BUFFALO, NY – June 20, 2025 – A new #review was #published in Volume 16 of Oncotarget on June 10, 2025, titled “Beyond DNA damage response: Immunomodulatory attributes of CHEK2 in solid tumors.” In this paper, led by first author Helen Qian and corresponding author Crismita Dmello from Northwestern University Feinberg School of Medicine, researchers compiled growing evidence that the CHEK2 gene, long known for its role in repairing DNA damage, may also influence how tumors respond to immunotherapy. Their analysis suggests that problems in CHEK2 function might make cancer cells more vulnerable to immune system attacks, highlighting a new opportunity to improve treatment outcomes in solid tumors. Immune checkpoint inhibitors (ICIs) have transformed cancer treatment; however, they are effective in only a subset of patients. This review suggests that tumors with reduced CHEK2 activity may accumulate more mutations that produce signals the immune system can recognize. These signals, known as neoantigens, help immune cells identify and destroy cancer cells more effectively. The review connects this process not only to CHEK2's established role in the DNA damage response but also to a newly proposed function in shaping the immune environment of tumors. CHEK2 normally helps maintain genomic stability by enabling precise DNA repair. When this function is lost, cells rely on more error-prone repair methods, leading to additional mutations. These mutations can increase tumor mutational burden, which has been linked to better outcomes with immunotherapy. Beyond DNA repair, the review highlights a second mechanism: activation of the cGAS-STING pathway. This pathway detects fragments of damaged DNA and triggers inflammation that attracts immune cells to the tumor. The authors highlight studies where CHEK2-deficient tumors responded better to PD-1 inhibitors, a common type of immune checkpoint inhibitor. In both lab models and early-stage clinical settings, CHEK2 loss was associated with increased infiltration of CD8+ T cells—immune cells essential for attacking cancer cells. In cancers such as glioblastoma and renal cell carcinoma, which are typically resistant to immunotherapy, reduced CHEK2 expression was linked with more favorable immune activity and higher expression of interferon-related genes. The compiled evidence points to CHEK2 as a potential biomarker for identifying patients likely to respond to immunotherapy. In addition, combining CHEK2 inhibitors with existing immunotherapies may enhance anti-tumor effects, particularly in cancers with limited treatment options. The review notes that some clinical trials using the CHEK1/2 inhibitor prexasertib alongside immune checkpoint therapies have already shown promising early results. “The initial results from this Phase I clinical trial support the immunomodulatory role of CHEK2 expression and even suggest CHEK2 potentiates immunosuppression.” Although more research is needed to confirm these mechanisms and improve treatment approaches, this review underscores the expanding role of DNA repair genes like CHEK2—not only in maintaining genome integrity but also in helping the immune system fight cancer. DOI - https://doi.org/10.18632/oncotarget.28740 Correspondence to - Crismita Dmello - stellacpak@outlook.com Video short - https://www.youtube.com/watch?v=C26pEBc0itk Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Apply for my high level private mentoring and coaching: http://leanneoaten.com/wholewomancoaching   Get my free class: Should I Stay or Go? https://awakeningwomensupport.kit.com/a52df3d035   Join the End the Cycle Waiting List for the next cohort leanneoaten.com/etcenrollment   Connect with Leanne on Social Media:    Instagram: www.instagram.com/awakeningwomenofficial/  Facebook: www.facebook.com/awakeningwomenofficial/ Youtube: https://www.youtube.com/theevolvedfeminine Website: leanneoaten.com  Leanne Oaten is a former Registered Professional Counsellor with a background in Counselling Psychology and has over 13 years of experience counselling and coaching women. Over the past 6+ years, she has focused her expertise on educating and helping women identify narcissistic abuse break free from destructive relationships, and transform their lives on the other side of divorce. Her mission is helping successful career-driven, entrepreneurial women and moms who want to reach new levels in their income, success, and health but their destructive, high-conflict relationship is holding them back. She works with powerhouse women who are ready to transform their lives on the other side of narcissistic abuse and turn their pain into power to create a new sense of purpose and fulfillment in their new chapter.  You can find out more about her and her offerings at leanneoaten.com

Dr Chris Chlebowski, author of The Virus and the Host, shares a thought-provoking look at how viruses influence the body and why individual responses to infection vary. We explore how factors like diet, toxins and inflammation shape immune resilience, and the role of the body's internal terrain. You'll also discover practical, naturopathic tools to help support long-term health and immunity. For more information and the show notes, head to the CNM podcast website. Stay updated by following CNM on:Website: https://www.cnmpodcast.com Instagram: https://www.instagram.com/collegeofnaturopathicmedicine/Facebook: https://www.facebook.com/CNM.UK/

Dr. Rizwan Romee is a Oncologist at the Dana-Farber Cancer Institute and Associate Professor at Harvard Medical School, where his research focuses on genetically manipulating NK cells to enhance their anti-tumor function. He talks about advances and challenges in engineering NK cells for cancer therapy. He also discusses using E. coli to deliver immune-activating cytokines to tumors.

VLOG June 16 US v. Sean Combs Day 24, summary witnesses and "Diddy drug mule" Brendan Paul, Juror 6 is out, another juror to be questioned. Week 5 book: https://play.google.com/store/books/details?id=j6VlEQAAQBAJ…EDNY today; UN should not be immune for supporting terrorism (or censorship)

This episode of High Performance Health is a powerful reminder that the true path to longevity isn’t found in chasing supplement stacks or living to 160—it’s about becoming immune to aging by mastering the fundamentals. Angela sits down with Dr Jenna Macciochi, immunologist, author, and high-performance breathwork coach, to explore how chronic inflammation, lifestyle, mindset, and motherhood all shape our biological age far more than we realize. Dr Jenna's new book Immune to Age presents a revolutionary framework: understanding the immune system as a dynamic force through the seasons of life—from birth to old age. In this heartfelt, science-rich conversation, Jenna and Angela dive into everything from burnout and HRV to intuition, parenting, alcohol, and the myth of the perfect biohacking protocol. This is the longevity conversation every woman needs to hear. KEY TAKEAWAYS: Chronic Inflammation: The Silent Driver of Aging : The immune system's slow burn of inflammation is the root cause behind most chronic diseases and early aging. The Parenting Connection: Children phase-lock to their mother’s HRV—your emotional regulation teaches them how to regulate themselves. Burnout & Intuition: Ignoring your intuition and pushing through stress leads to burnout. Slowing down and listening is the real path to resilience. Longevity Isn’t Just About Data: Healthspan matters more than lifespan. Fancy tests are fun, but it’s the basics—food, movement, sleep, breath—that move the needle. Alcohol, Sleep & Energy: Giving up alcohol even temporarily can have a massive ripple effect on mood, energy, and parenting. Immune System Through the Life Course: From womb to old age, your immune system evolves—and it’s never too early or too late to care for it. TIMESTAMPS AND KEY TOPICS: 0:00 – Introduction 3:49 – Why healthspan matters more than lifespan 8:34 – Advice for working women juggling everything 12:15 – How meditation rewires stress and physiology 16:42 – Garbage time, HRV, and parenting insights 22:23 – Female intuition, hormones & relationships 29:10 – Jenna’s daily health and movement routine 34:28 – Alcohol and the “tiny experiment” approach 41:52 – Jenna’s new book: Immune to Age 49:37 – Cancer, inflammation & microbiome connection 59:24 – How to filter conflicting wellness advice 1:00:16 – Tests that matter (and those that don’t) VALUABLE RESOURCES Get a free snapshot of your health and personalised report at www.yourtotalhealthcheck.com Join The High Performance Health Community Click here for discounts on all the products I personally use and recommend A BIG thank you to our sponsors who make the show possible: LVLUP HEALTH: Slow aging, repair gut health boost collagen and recovery and more with LVLUP Health’s amazing products. Save 15% with code ANGELA at https://lvluphealth.com/angela Get 20% off the Creatine I love at trycreate.co/ANGELA20, and use code ANGELA20 to save 20% on your firsts order. Sign Up to Angela’s Weekly Fresh Starts Email to transform your health, energy, and longevity with just ONE small habit every week - angelafoster.me/freshstart Pre order Dr Jenna’s book: Immune To Age: The Game Changing Science of Immune Health (releasing on 3rd July 2025) ABOUT THE GUEST Based in Brighton, Dr Jenna is a Senior Lecturer in Immunology at The University of Sussex and a fitness instructor and health coach. She integrates her extensive academic knowledge with practical experience, guiding individuals and businesses in the wellness and performance sectors. A certified high-performance breathwork coach, Jenna provides functional breathing assessments and breath training to help clients unlock their full potential and enhance physical and mental well-being and performance. Her expertise in supplement formulation benefits individuals seeking targeted supplement protocols and bloodwork analysis for their health goals. Her expertise in supplement formulation can assist businesses in creating compliant, scientifically-backed health products. She is the author of two seminal books "Immunity: The Science of Staying Well" (Harper Collins, 2020) and "Your Blueprint for Strong Immunity" (Yellow Kite, 2022). Her books combine cutting-edge research with practical advice, making them essential reads for anyone looking to live a healthier life. Jenna loves crafting recipes and rituals inspired by her farm-to-table Scottish roots and capturing her family’s Italian heritage. As a mother of twins and a keen home cook, she brings a personal and realistic touch to her scientifically-baked advice. ABOUT THE HOST Angela Foster is an award winning Nutritionist, Health & Performance Coach, Speaker and Host of the High Performance Health podcast. A former Corporate lawyer turned industry leader in biohacking and health optimisation for women, Angela has been featured in various media including Huff Post, Runners world, The Health Optimisation Summit, BrainTap, The Women’s Biohacking Conference, Livestrong & Natural Health Magazine. Angela is the creator of BioSyncing®️ a blueprint for ambitious entrepreneurial women to biohack their health so they can 10X how they show up in their business and their family without burning out. The High Performance Health Podcast is a top rated global podcast. Each week, Angela brings you a new insight, biohack or high performance habit to help you unlock optimal health, longevity and higher performance. Hit the follow button to make sure you get notified each time Angela releases a new episode. CONTACT DETAILS Instagram Facebook LinkedIn Affiliate Disclaimer: Note this description contains affiliate links that allow you to find the items mentioned in this video and support the channel at no cost to you. While this channel may earn minimal sums when the viewer uses the links, the viewer is under no obligation to use these links. Thank you for supporting the show! Disclaimer: The High Performance Health Podcast is for general information purposes only and do not constitute the practice of professional or coaching advice and no client relationship is formed. The use of information on this podcast, or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for medical or other professional advice, diagnosis, or treatment. Users should seek the assistance of their medical doctor or other health care professional for before taking any steps to implement any of the items discussed in this podcast. This Podcast has been brought to you by Disruptive Media. https://disruptivemedia.co.uk/

In this encore episode, we detail the gut-immune axis, focusing on the protective mucus layer and the role of lactoferrin in intestinal health. We discuss endogenous secretions and how lactoferrin functions as an antimicrobial, immunomodulatory, and iron-regulating glycoprotein, influencing microbial balance and intestinal barrier integrity. Additionally, we highlight lactoferrin testing and levels. We finish by going through supplementation as a phenomenal tool.Topics: 1. The Intestinal Barrier & Mucus Layer- The intestinal lumen, microbiome, mucus layer, epithelial cells, and lamina propria.- The mucus layer: antimicrobial peptides (AMPs) and secretory IgA (sIgA).- Intestinal epithelial cells including goblet cells and enterocytes.2. Immune Cells in the Gut- The lamina propria.- Macrophages, dendritic cells, neutrophils, B cells, T cells, mast cells, and more.3. Antimicrobial Peptides & Secretory IgA- AMPs and sIgA in the mucus layer regulate microbial balance and prevent pathogen adhesion.4. Lactoferrin: Functions & Sources- Iron-binding glycoprotein, antimicrobial and immunomodulatory properties.- Found in mucosal secretions, colostrum, and more.- Intestinal epithelial cells (IECs) and neutrophils.5. Lactoferrin's Role in Intestinal Health- Regulates iron absorption via lactoferrin receptors (LFR)on enterocytes.- Sequesters free iron, limiting bacterial growth, bacteriostatic.- Destabilizes bacterial membranes, cell lysis, bactericidal.6. Lactoferrin Levels- Neutrophils release lactoferrin during infection,increasing its presence in the large intestine.- Fecal lactoferrin levels.- Fecal calprotectin levels.7. Lactoferrin & Candida Overgrowth- Fungal membranes.- Aiding in the inhibition of biofilm formation.8. Lactoferrin Supplementation & Benefits- Supports gut microbiota, epithelial integrity, and immune modulation.- Bovine colostrum and as a supplement.9. Conclusion- The intestinal mucus layer is key to gut barrier function.- Lactoferrin plays a central role in microbial regulation and immune defense.Get Chloe's Book Today! "⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠75 Gut-Healing Strategies & Biohacks⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠" Follow Chloe on Instagram ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@synthesisofwellness⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠synthesisofwellness.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

On this episode of the Integrative Cancer Solutions podcast Dr. Karlfeldt interviews Dr. Francisco Contreras. Dr. Contreras shares his background, explaining that his father founded their clinic in 1963, introducing a holistic approach to cancer treatment that addresses emotional and spiritual needs alongside physical ones. He recounts significant success stories, including a patient with advanced breast cancer who improved dramatically using alternative therapies. Dr. Contreras received training in Vienna and follows his father's intuitive approach of combining conventional and non-conventional methods. The discussion highlights the complexity of cancer as a disease and the importance of addressing the immune system for long-term treatment success. Dr. Contreras explains various therapies used at the Oasis of Hope, including dendritic cell vaccines, natural killer cells, and tumor infiltrating lymphocytes. He emphasizes the non-toxic nature of cell therapies and their cost-effectiveness in Mexico compared to the United States. The conversation also covers the combination of conventional and alternative treatments, such as low-dose chemotherapy to make tumors more visible to the immune system, along with additional therapies like high-dose vitamin C, vitamin B17, and hyperthermia. Dr. Contreras concludes by explaining the patient consultation process and offering his book "The Art and Science of Undermining Cancer" as a resource for listeners.Dr. Francisco Contreras discusses his family's pioneering work in integrative cancer treatment at Oasis of Hope, founded by his father in 1963, combining conventional medicine with holistic approaches.The podcast emphasizes treating cancer as a metabolic disease rather than just targeting genetic mutations, with special focus on strengthening the immune system for long-term success.Dendritic cell therapy and other cell-based treatments are highlighted as effective, non-toxic approaches that can be more affordable in Mexico than similar treatments in the United States.Dr. Contreras explains how low-dose metronomic chemotherapy can be strategically combined with immune therapies to make tumors more visible to the immune system while reducing regulatory T cells.Additional therapies discussed include high-dose vitamin C, vitamin B17, and hyperthermia, which have contributed to improved five-year survival rates for stage four cancer patients at their clinic.----Grab my book A Better Way to Treat Cancer: A Comprehensive Guide to Understanding, Preventing and Most Effectively Treating Our Biggest Health Threat - https://www.amazon.com/dp/B0CM1KKD9X?ref_=pe_3052080_397514860 Unleashing 10X Power: A Revolutionary Approach to Conquering Cancerhttps://store.thekarlfeldtcenter.com/products/unleashing-10x-power-Price: $24.99-100% Off Discount Code: CANCERPODCAST1Healing Within: Unraveling the Emotional Roots of Cancerhttps://store.thekarlfeldtcenter.com/products/healing-within-Price: $24.99-100% Off Discount Code: CANCERPODCAST2----Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VEY865. CME/MOC/AAPA/IPCE credit will be available until June 22, 2026.An Immune Reset for Systemic Lupus Erythematosus: Expanding Therapeutic Horizons With CAR-T Cell Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VEY865. CME/MOC/AAPA/IPCE credit will be available until June 22, 2026.An Immune Reset for Systemic Lupus Erythematosus: Expanding Therapeutic Horizons With CAR-T Cell Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

From the 2024 Society for Leukocyte Biology meeting, Cindy and Brianne sit down with Justin Wilson to talk about how he got into research and his more recent studies on innate immune sensors and the interaction between the gut microbiome and inflammation related to inflammatory bowel disease and cancer. Hosts: Cindy Leifer and Brianne Barker Guest: Justin Wilson Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server Francisella tularensis undermining macrophage defenses (Infect Immunity) AIM2 suppressing colon cancer (Nature Med) NLRP12 regulates gut microbiota homeostasis (Cell Host Microbe) Oral bacteria and carcinogenesis connection (Microbiol Mol Bio Rev) Society for Leukocyte Biology Time stamps by Jolene Ramsey. Thanks! Music by Tatami. Logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv Information on this podcast should not be construed as medical advice.

 Immune Health and Allergies ..think 5 in 1 Qummune for Year round support!Flavonoids..... Let's start with one that is classified as a Flavonoid, and thatis Quercetin.We also dive into Liposomal delivery,Do you have allergies and immune issues?  → Can Quercetin be found in food?→ What is the difference between Quercetin & Quercetin Phytosome?→ What are branded ingredients? → Vitamin C is also a go to for people hoping to supportdaily Immune function. But not all Vitamin C is the same.→ Zinc rich foods people can add in? → D3/K2-Why should they be taken together??→ Absorption seems to be the key whether it be food or Supplements.→ Lab tested and certified for potency and purity. Why isthis important?Guest: Amber Lynn Vitale, CN is Board Certified in Holistic Nutrition®and a Certified Dietary Supplement Professional™. She is also anAyurvedic Clinical Consultant on faculty with Wild Rose College ofHerbal Medicine, and on the advisory board for Natural Practitionerand Taste for Life magazines.Amber's journey in the healing arts developed richly as she workedfor years in practices with Integrative Physicians, Acupuncturists,Chiropractors, and Nurses. Since 2008 she has been producingwritten and video educational content for many publications, aneducational YouTube channel, and Instagram and Facebook pages.By 2012 she had realized that raw materials sourcing, labelingtransparency, legitimate certifications, and educational supportwere the criteria that would set quality natural products brandsapart from the rest; and she made it her mission to educateboth the practitioner and the public about the standards thatensure a reliable product.  Recently she founded Trifecta ForHealth, LLC using her years of experience to develop synergistichealth protocols tailored to individual needs, and provide brandsupport for the best supplemental products currently available.Learn more about Amber  Learn More about Qummune 5 in 1 Immune Support (Use the code Forever25 to save 25% OFF)  Read the research

Dr. Jeff Bland has been a guiding force in my life—and in the world of Functional Medicine. For decades, his work has helped shift medicine away from naming and blaming disease, toward truly understanding and addressing its root causes. In this episode of The Dr. Hyman Show, Jeff and I continue our conversation about how to turn the tide on chronic disease—starting with the immune system. We discuss: • How aging quietly weakens your immune system—and why you don't have to accept it • How phytochemicals act as gene regulators—not just antioxidants • Why your diet might be accelerating immune dysfunction (and how to fix it) • Why Himalayan Tartary Buckwheat may be the most powerful food you're not eating (yet) • What it means to rejuvenate your immune system—and how to start doing it today This conversation is personal for both of us—and a powerful reminder that when we care for the body, it has an incredible capacity to heal. View Show Notes From This EpisodeGet Free Weekly Health Tips from Dr. Hyman https://drhyman.com/pages/picks?utm_campaign=shownotes&utm_medium=banner&utm_source=podcast Sign Up for Dr. Hyman's Weekly Longevity Journal https://drhyman.com/pages/longevity?utm_campaign=shownotes&utm_medium=banner&utm_source=podcast Join the 10-Day Detox to Reset Your Healthhttps://drhyman.com/pages/10-day-detoxJoin the Hyman Hive for Expert Support and Real Resultshttps://drhyman.com/pages/hyman-hive This episode is brought to you by BON CHARGE, Big Bold Health, Pique, PerfectAmino and AirDoctor. Go to boncharge.com and use code DRMARK to save 15% on your PEMF mat today. Try Omega-3 Rejuvenate®, visit bigboldhealth.com and use code DRMARK25 at checkout for 25% discount. Head to piquelife.com/hyman to get 20% off + a free beaker and frother today. Get pure essential amino acids today. Go to bodyhealth.com and use HYMAN20 to get 20% off your first order. Get cleaner air. Right now, you can get up to $300 off at airdoctorpro.com/drhyman.

Add the best superfood for immunity to your diet today! Discover the countless health benefits of colostrum for your immune system, gut health, and more. Learn about the benefits of colostrum for adults and aging populations. It's not just for babies!0:00 Introduction: The best superfood for immunity 0:44 What is colostrum? 1:12 Colostrum benefits 3:33 Colostrum for adults3:43 Colostrum and gut health4:01 More colostrum uses 4:54 How to take colostrumColostrum is produced in the first 24 to 72 hours after birth. It's golden in color and rich in essential probiotics, including L. reuteri. It's significantly more immune-building than regular milk and even contains stem cells. Colostrum also contains an important prebiotic called HMO (human milk oligosaccharides) that feeds the probiotics found in breast milk. Colostrum contains cholesterol and omega-3 fats, vital for brain health, and important hormones like oxytocin and cortisol.Many infants are fed infant formula, which is essentially ultra-processed food calories. Most infant formulas are made of low-quality ingredients such as maltodextrin and soy, and they lack the immune benefits and probiotics of breast milk. Children who were fed infant formula are more predisposed to allergies, asthma, skin problems, obesity, cognitive delays, and other health problems. If you didn't get colostrum as a baby, there are still many benefits of colostrum for adults. You can take colostrum in supplement form. Colostrum is beneficial for gut health and can help fix a leaky gut or gut damage. It can help lower inflammation, increase good microbes, and decrease pathogens. Colostrum has powerful benefits for respiratory problems such as allergies and asthma. It can also help an overactive immune system and many autoimmune conditions. Colostrum helps support the thymus glands as you age and is very beneficial for age-related problems such as muscle loss, wrinkles, macular degeneration, and arthritis. It can even help with long COVID, Hashimoto's, autism, and Lyme disease. Colostrum is heat-sensitive, so look for a freeze-dried supplement!Dr. Eric Berg DC Bio:Dr. Berg, age 60, is a chiropractor who specializes in Healthy Ketosis & Intermittent Fasting. He is the author of the best-selling book The Healthy Keto Plan, and is the Director of Dr. Berg Nutritionals. He no longer practices, but focuses on health education through social media.

In this episode, I sit down with Dr. Nicole Cain to talk about her integrative, trauma-informed approach to anxiety and mental wellness. We explore how anxiety shows up in the body—through our thoughts, hormones, immune system, and gut—and what it takes to truly heal at the root.Nicole shares insights from her book Panic Proof along with powerful tools like EMDR, hormone testing, and Ayurveda. Whether you're navigating anxiety yourself or supporting someone who is, this conversation is packed with practical, whole-person strategies to find calm and reclaim your mental health.Leave Us A Voice Message! | https://telbee.io/channel/4_b9zzx58wdkuwirqkcxwa/Topics Discussed:What is the root cause of anxiety and how can it be healed naturally?How does gut health affect mental health and anxiety?What is Dr. Nicole Cain's approach to managing anxiety with integrative medicine?What is the connection between hormone imbalances and anxiety symptoms?Sponsored By:Be Well By Kelly Protein Powder & Essentials | Get $10 off your order with PODCAST10 at bewellbykelly.com.AG1 | Get a FREE 1-year supply of Vitamin D3+K2 AND 5 free AG1 Travel Packs with your first subscription at drinkAG1.com/bewell.Jesse & Ben's | Right now, you can visit jesseandbens.com/bewell for a special deal.OneSkin | Visit oneskin.co/BEWELL and use code BEWELL for 15% off your first purchase.Timestamps:00:00:00 - Introduction 00:00:00 – Episode intro with Dr. Nicole Cain00:01:41 – What is anxiety? Root causes explained00:05:49 – Kelly's personal anxiety journey00:09:02 – Understanding the window of tolerance00:10:36 – Anxiety, autonomy, and creative power00:13:22 – Why suppressed emotions intensify anxiety00:14:37 – Dr. Nicole's story of living with anxiety00:19:30 – What is thought anxiety?00:24:32 – Tools to overcome thought anxiety00:26:02 – Endocrine anxiety and stress hormones00:32:21 – Hormonal imbalance, anxiety & HRT00:35:35 – DUTCH testing00:37:21 – Immune system's link to anxiety00:40:34 – Gut-brain axis and mental health00:42:13 – Lifestyle changes for anxiety relief00:43:32 – Dr. Nicole's full intake process00:49:31 – Using Ayurveda and Kapha for anxiety00:51:58 – Exercises to calm anxiety naturally00:57:55 – Brain science: prefrontal cortex vs. lizard brain01:01:55 – Interoception and body awareness01:06:28 – How to become panic proofFurther Listening:Prioritizing Hormonal Health with Dr. Carrie JonesCheck Out Dr. Nicole: InstagramBook - To Shop